BioSpace News Archive

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults.

Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted).

BioReference® Health, LLC, a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data for the pharmaceutical and life science industries.

AmacaThera announced the closing of a CAD$4.0 million financing round.

Oncotelic Therapeutics, Inc announced today its Chief Executive Officer (“CEO”), Dr. Vuong Trieu, will be a featured speaker at the upcoming Ibero-American Chatbot and Conversational AI Summit.

PDS Biotechnology Corporation today announced the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023.

NLS Pharmaceutics Ltd. today announced that, subject to final approval of the extraordinary general meeting taking place on December 22, 2023, the Company’s board of directors (the “Board”) has elected Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join the Board effective January 1, 2024.

Better Therapeutics, Inc., a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, disclosed several initiatives aimed at extending the company’s cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx.

eFFECTOR Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for zotatifin.

ReWalk Robotics, Ltd. announced the successful demonstration of a proof-of-concept next-generation exoskeleton.